Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 14;108(8):1929-1936.
doi: 10.1210/clinem/dgad079.

GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?

Adrien Nguyen Quoc  1   2 , Kévin Beccaria  2   3 , Laura González Briceño  1 , Graziella Pinto  1 , Dinane Samara-Boustani  1 , Athanasia Stoupa  1   4   5 , Jacques Beltrand  1   2   4   5 , Alix Besançon  1 , Caroline Thalassinos  1 , Stéphanie Puget  2   3 , Thomas Blauwblomme  2   3 , Claire Alapetite  6   7 , Stéphanie Bolle  8   9 , François Doz  2   10 , Jacques Grill  11 , Christelle Dufour  11 , Franck Bourdeaut  10 , Samuel Abbou  11 , Léa Guerrini-Rousseau  11 , Amaury Leruste  10 , Séverine Brabant  12 , Iphigénie Cavadias  1 , Magali Viaud  1 , Nathalie Boddaert  2   13 , Michel Polak  1   2   4   5 , Dulanjalee Kariyawasam  1   2   4   5
Affiliations

GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?

Adrien Nguyen Quoc et al. J Clin Endocrinol Metab. .

Erratum in

Abstract

Context: Craniopharyngioma is a benign brain tumor with frequent local recurrence or progression after treatment. GH replacement therapy (GHRT) is prescribed in children with GH deficiency resulting from childhood-onset craniopharyngioma.

Objective: To evaluate whether a shorter delay of GHRT initiation after childhood-onset craniopharyngioma completion therapy increased the risk of a new event (progression or recurrence).

Methods: Retrospective, observational, monocenter study. We compared a cohort of 71 childhood-onset patients with craniopharyngiomas treated with recombinant human GH (rhGH). Twenty-seven patients were treated with rhGH at least 12 months after craniopharyngioma treatment (>12-month group) and 44 patients before 12 months (<12-month group), among which 29 patients were treated between 6 and 12 months (6-12 month group). The main outcome was the risk of tumor new event (progression of residual tumor or tumor recurrence after complete resection) after primary treatment in the >12-month group and in the <12 month or in the 6- to 12-month group patients.

Results: In the >12-month group, the 2- and 5-year event-free survivals were respectively 81.5% (95% CI, 61.1-91.9) and 69.4% (95% CI, 47.9-83.4) compared with 72.2% (95% CI, 56.3-83.1) and 69.8% (95% CI, 53.8-81.2) in the <12-month group. The 2- and 5-year event-free survivals were the same in the 6- to 12-month group (72.4%; 95% CI, 52.4-85.1). By log-rank test, the event-free survival was not different between groups (P = .98 and P = .91).The median time for event was not statistically different.In univariate and multivariate analysis, the risk of craniopharyngioma new event was not associated with the GHRT time delay after craniopharyngioma treatment.

Conclusions: No association was found between GHRT time delay after childhood-onset craniopharyngioma treatment and an increased risk of recurrence or tumor progression, suggesting GH replacement therapy can be initiated 6 months after last treatment for craniopharyngiomas.

Keywords: growth hormone; growth hormone safety; pediatric craniopharyngioma; tumor recurrence.

PubMed Disclaimer

Publication types

MeSH terms

Substances